

KAPLAN FOX & KILSHEIMER LLP

Lawrence King (SBN 206423)

lking@kaplanfox.com

Mario M. Choi (SBN 243409)

mchoi@kaplanfox.com

350 Sansome Street, Suite 400

San Francisco, CA 94104

Telephone: (415) 772-4700

Facsimile: (415) 772-4707

KAPLAN FOX & KILSHEIMER LLP

Maia C. Kats (to be admitted *pro hac vice*)

mkats@kaplanfox.com

6109 32nd Place, NW

Washington, DC 20015

Telephone: (202) 669-0658

REESE LLP

Michael R. Reese (SBN 206773)

mreese@reesellp.com

George V. Granade (SBN 316050)

ggranade@reesellp.com

100 West 93rd Street, 16th Floor

New York, New York 10025

Telephone: (212) 643-0500

Facsimile: (212) 253-4272

*Counsel for Plaintiffs Richa Arora, Randy Clinton,
and Walter Johnston and the Proposed Class*

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA**

**RICHA ARORA, RANDY CLINTON, and
WALTER JOHNSTON, individually and on
behalf of all others similarly situated,**

Plaintiffs,

v.

GNC HOLDINGS, INC.,

Defendant.

Case No. 3:19-cv-02414

CLASS ACTION COMPLAINT

Demand for Jury Trial

1 Plaintiffs Richa Arora, Randy Clinton, and Walter Johnston (collectively, “Plaintiffs”),
 2 individually and on behalf of all others similarly situated, bring this class action complaint against
 3 GNC Holdings, Inc. (“Defendant” or “GNC”), and on the basis of personal knowledge,
 4 information and belief, and investigation of counsel, allege as follows:

5 **NATURE OF THE ACTION**

6 1. This action seeks to recover for injuries suffered by Plaintiffs and all others
 7 similarly situated (the “Class,” as defined below) as a direct result of GNC’s unlawful, deceptive,
 8 and misleading labeling, marketing, and sale of GNC proprietary brand dietary supplements
 9 (“GNC proprietary brand supplements” or the “Supplements”), including, but not limited to, GNC
 10 Men’s Prostate Formula Dietary Supplement (“Prostate Health”), GNC Diabetic Support Dietary
 11 Supplement (“Diabetic Support”), GNC Preventive Nutrition Healthy Blood Pressure Formula
 12 Supplement, GNC Women’s Ultra Mega Active Supplement, and GNC Mega Men Healthy
 13 Testosterone (“Mega Men Performance”).

14 2. Plaintiffs assert three types of claims. First, they assert “unlawful” claims because
 15 GNC marketed, labeled, and sold misbranded Supplements in violation of the Federal Food, Drug,
 16 and Cosmetic Act of 1938, 21 U.S.C. § 301 *et seq.* (the “FFDCA” or the “Act”), as amended by
 17 the Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103–417, 108 Stat. 4325
 18 (“DSHEA”), as well as the regulations implementing the FFDCA and DSHEA. These
 19 requirements are fully incorporated into California’s Sherman Food, Drug, and Cosmetic Law,
 20 CAL. HEALTH & SAFETY CODE § 109875 *et seq.* (“Sherman Law”), and actionable pursuant to the
 21 unlawful prong of California’s Unfair Competition Law, CAL. BUS. & PROF. CODE § 17200 *et seq.*
 22 (“UCL”).

23 3. Second, Plaintiffs assert “misleading and deceptive” marketing claims because
 24 GNC labeled, marketed, and sold the Supplements in a manner that is unfair, deceptive, and untrue
 25 in violation of California’s UCL and New York’s Consumer Protection from Deceptive Acts and
 26 Practices Law, N.Y. GEN. BUS. LAW § 349 *et seq.*

27 4. Third, Plaintiffs assert common law claims for unjust enrichment.
 28

5. With respect to Plaintiffs’ “unlawful” claims, GNC is prohibited from labeling, marketing, or selling dietary supplements bearing claims that “describe[] the role of a nutrient or dietary ingredient intended to affect the structure or function in humans, [or that] characterize[] the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function” (known as “structure/function claims”), unless the label carries a prominent disclaimer on each panel bearing such claims. *See* 21 U.S.C. §§ 321(g)(1), 331(d), 343(r)(1)(B), 343(r)(6), 355(a); 21 C.F.R. § 101.93(d) (“On product labels and in labeling (e.g., pamphlets, catalogs), the disclaimer shall appear on each panel or page where there [is a structure/function claim].”).

6. The disclaimer must be prominent and bolded, and it must read:

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

21 U.S.C. § 343(r)(6)(C); *see also* 21 C.F.R. § 101.93(b)-(e).

7. Because GNC Supplements do not bear the required disclaimers on all panels with structure/function claims, and/or the disclaimer lacks the prominence required, the Supplements are misbranded and unlawful. 21 U.S.C. § 343(r)(1)(B), (r)(6); 21 C.F.R. § 101.93(d).

8. GNC Supplements also qualify as “drugs” under the FFDCA since GNC markets them with structure/function claims but does not include the disclaimers. *See* 21 U.S.C. §§321(g)(1), 343(r)(6). In order to avoid being regulated as drugs under the FFDCA, dietary supplements bearing structure/function claims must comply with the disclaimer requirements. *Id.*

9. Drugs require pre-market approval from the federal Food & Drug Administration (“FDA”). 21 U.S.C. §§ 331(d), 355(a).

10. Upon information and belief, GNC lacks pre-market approval for its Supplements, rendering them not just misbranded but unapproved drugs.

11. Misbranded dietary supplements and/or unapproved drugs are unlawful and cannot be sold legally. 21 U.S.C. §§ 331, 333. Under Section 110760 of the Sherman Law, they have no economic value and are worthless.

12. With respect to Plaintiffs’ “deceptive and misleading” claims, GNC deceptively labels, markets, and sells the Supplements as having been subjected to the FDA’s pre-market

1 approval process; and/or intended to prevent, cure, or treat a disease or health-related condition
2 linked to disease.

3 13. GNC compounds its deception by coupling its omission of the disclaimer with
4 misleading phrases like “clinically studied,” “scientifically designed,” “physician formulated,” or
5 “physician endorsed,” and with medical symbols, and/or by referencing diseases and/or conditions
6 equated with disease in its marketing of the Supplements.

7 14. Plaintiffs and the members of the Class reviewed and reasonably relied on GNC’s
8 Supplement labels and packaging when purchasing them and were misled by GNC’s marketing.

9 15. Had Plaintiffs known that the Supplements were misbranded, unlawful, lacked
10 government review and approval, and/or were not intended to treat, cure, or prevent any disease
11 (that is, were not intended for therapeutic purposes), Plaintiffs would not have purchased them.

12 16. Owing to their reliance on GNC’s deceptive labeling, marketing, and sales of the
13 Supplements, Plaintiffs and the members of the Class purchased GNC Supplements believing
14 them to have characteristics and qualities that they do not have. Plaintiffs and the members of the
15 Class have been injured because they would not have purchased the Supplements or paid as much
16 for them had they known the truth.

17 **PARTIES**

18 **A. Plaintiffs**

19 17. Plaintiff Richa Arora is a resident of San Francisco, California.

20 18. During the relevant class period, Ms. Arora purchased GNC Prostate Health
21 Supplement for her father, GNC Women’s Ultra Mega Active Supplement for herself, and other
22 Supplements, from a GNC location at the Northpoint Shopping Center, 350 Bay Street, San
23 Francisco, California 94133, in addition to other purchases.

24 19. Ms. Arora believed that the Supplements were lawful, correctly branded, subject to
25 a governmental review and approval process, and had therapeutic value, including that they were
26 intended to prevent or treat disease, including prostate disease.

27 20. Ms. Arora relied on GNC’s marketing of the Supplements, both implied and
28 express, when making her purchases.

1 21. Ms. Arora paid more for, and purchased more of, GNC Supplements than she
2 would have had she known the truth about them.

3 22. Ms. Arora was injured in fact and lost money as a result of Defendant's improper
4 and unlawful conduct.

5 23. If Ms. Arora knew that GNC's marketing and sale of the Supplements was lawful,
6 truthful, and non-misleading, she would purchase the Supplements in the future. At present,
7 however, Ms. Arora cannot purchase the Supplements because she cannot be confident that they
8 are lawful and that their labeling is truthful and non-misleading.

9 24. Plaintiff Randy Clinton is a resident of Tracy, California.

10 25. During the relevant class period, Mr. Clinton purchased GNC Diabetic Support
11 Supplement, and other Supplements, from a GNC location at the West Valley Mall, 3200 North
12 Naglee Road, Tracy, California 95304.

13 26. Mr. Clinton believed that the Supplements were lawful, correctly branded, subject
14 to a governmental review and approval process, and had therapeutic value, including that they
15 were intended to prevent or treat disease, including diabetes.

16 27. Mr. Clinton relied on GNC's marketing of the Supplements, both implied and
17 express, when making his purchases.

18 28. Mr. Clinton paid more for, and purchased more of, GNC Supplements than he
19 would have had he known the truth about them.

20 29. Mr. Clinton was injured in fact and lost money as a result of Defendant's improper
21 and unlawful conduct.

22 30. If Mr. Clinton knew that GNC's marketing and sale of Supplements was lawful,
23 truthful, and non-misleading, he would purchase the Supplements in the future. At present,
24 however, Mr. Clinton cannot purchase the Supplements because he cannot be confident that they
25 are lawful and that their labeling is truthful and non-misleading.

26 31. Plaintiff Walter Johnston is a resident of Jamestown, New York.
27
28

1 32. During the relevant class period, Mr. Johnston purchased GNC Mega Men
2 Performance and Vitality Mega Vitapaks, among other Supplements, from a GNC location in
3 Chautauqua Mall, 318 East Fairmont Avenue, Lakewood, New York 14750, and in Pennsylvania.

4 33. Mr. Johnston believed GNC's representations that the Supplements had therapeutic
5 value with respect to his prostate, circulation, and overall medical health.

6 34. In purchasing the Supplements, he relied on GNC's representations that the
7 Supplements had therapeutic value with respect to his prostate, circulation, and overall medical
8 health.

9 35. Mr. Johnston purchased more of, or paid more for, GNC Supplements than he
10 would have had he known the truth about the products.

11 36. Mr. Johnston was injured in fact and lost money as a result of Defendant's
12 improper and unlawful conduct.

13 37. If Mr. Johnston knew GNC Supplement labels and advertising were lawful,
14 truthful, and non-misleading, he would purchase GNC Supplements in the future. At present,
15 however, Mr. Johnson cannot purchase the products because he cannot be confident that the sales,
16 labeling, and advertising of the products are, and will be, lawful, truthful, and non-misleading.

17 **B. Defendant**

18 38. Defendant GNC Holdings, Inc., is a public corporation organized and existing
19 under the laws of the State of Delaware.

20 39. Defendant's principal place of business is at 300 Sixth Avenue, Pittsburgh,
21 Pennsylvania 15222.

22 40. Defendant owns, operates, and franchises retail locations under the name "GNC."
23 Approximately 2,989 of 4,026 GNC retail stores in the United States are owned and managed by
24 GNC. There are 269 company-owned stores in California.

25 41. Both with respect to corporate-owned retail stores and franchises, Defendant directs
26 and requires that all retail locations display and offer for sale GNC Supplements, and directs all
27 marketing and labeling thereof.
28

JURISDICTION

42. This Court has original subject-matter jurisdiction over this proposed class action pursuant to the Class Action Fairness Act of 2005, Pub. L. No. 109-2, 119 Stat. 4, which provides for the original jurisdiction of federal district courts over “any civil action in which the matter in controversy exceeds the sum or value of \$5,000,000, exclusive of interest and costs, and [that] is a class action in which . . . any member of a class of plaintiffs is a citizen of a State different from any defendant.” 28 U.S.C. § 1332(d)(2)(A). Because Plaintiff Arora is a citizen of the State of California and Defendant is a citizen of the States of Delaware and Pennsylvania, at least one member of the plaintiff Class is a citizen of a state different from Defendant. Further, Plaintiffs allege the matter in controversy is well in excess of \$5,000,000 in the aggregate, exclusive of interest and costs. Finally, Plaintiffs allege “the number of members of all proposed plaintiff classes in the aggregate” is greater than 100. *See* 28 U.S.C. § 1332(d)(5)(B).

43. This Court has personal jurisdiction over Defendant for several reasons, including that GNC has continuous and systematic contacts with California, in part because approximately 269 Defendant-owned GNC stores are located in California; and Plaintiffs’ claims arise out of Defendant’s conduct within California, in part because Plaintiffs Arora and Clinton purchased GNC Supplements within California based on Defendant’s unlawful marketing and dissemination of false and misleading information about them.

VENUE

44. Venue is proper in this District pursuant to 28 U.S.C. § 1391(b)(2). A substantial part of the events or omissions giving rise to Plaintiff Arora’s claims occurred within this District, including her purchases of Supplements based on GNC’s unlawful and deceptive marketing.

INTRADISTRICT ASSIGNMENT

45. Assignment to the San Francisco Division is appropriate under Civil Local Rule 3-2(c) and (d) because a substantial part of the events or omissions which gave rise to Plaintiff Arora’s claims occurred within San Francisco County, including Ms. Arora’s purchases of GNC Supplements based on GNC’s unlawful and deceptive marketing.

FACTUAL ALLEGATIONS

46. GNC, along with its subsidiaries, is the leading retailer of health, wellness, and performance products, including dietary supplements, in the world. GNC sells both proprietary brand dietary supplements and third party brands and has approximately 9,000 locations worldwide, with 4,000 in the United States.

47. The dietary supplements business is highly profitable. For 2018, GNC reported earnings of approximately \$3 billion.

48. GNC's dietary supplement business has been the subject of multiple investigations and claims of consumer deception and fraud.

49. In February 2015, for example, then-New York Attorney General Schneiderman ordered GNC to cease and desist its practice of deceptively labeling dietary supplements. The Office of the New York Attorney General and GNC reached an agreement in September 2016, which required GNC to test its supplements more robustly to ensure the authenticity of ingredients and accuracy of labeling claims.¹

50. In October 2015, the Attorney General of Oregon filed a lawsuit against GNC alleging that the company knowingly sold products containing picamilon and BMPEA, ingredients banned by the FDA as unsafe.²

51. In February 2017, Fox Broadcasting Company rejected GNC advertisements scheduled to run during Superbowl LI because the National Football League Players' Association placed GNC on its blacklist—warning against business relations with GNC—for selling products that contain substances banned by the National Football League.³

¹ *A.G. Schneiderman Announces Major Nationwide Agreement with NBTY, Herbal Supplement Maker for Walgreens and Walmart*, AG.NY.GOV (Sept. 28, 2016), <https://on.ny.gov/2W12qQF>.

² Sara Germano & Serena Ng, *Oregon Sues GNC, Alleging Supplements Contained Illegal Ingredients*, WALL STREET J., Oct. 22, 2015, available at <https://on.wsj.com/2GvBVwo>.

³ Alexandra Bruell, *GNC's Super Bowl Ad Rejected by NFL*, WALL STREET J., Jan. 31, 2017, available at <https://on.wsj.com/2vh0w2J>.

A. GNC’s Unlawful Labeling, Marketing, and Sale of Its Proprietary Brand Supplements.

52. Under section 201(g)(1)(B) and (g)(1)(C) of the FFDCA (codified at 21 U.S.C. § 321(g)(1)(B) and (g)(1)(C)), a “drug” is defined, in part, as an “article[] intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals,” *or* an “article[] (other than food) intended to affect the structure or any function of the body of man or other animals.”

53. New “drugs” require approval by the FDA prior to placement on the market. *See* 21 U.S.C. §§ 331(d), 355(a).⁴

54. Section 403(r)(6) of the FFDCA (codified at 21 U.S.C. § 343(r)(6)), creates an exemption from drug treatment—that is, an exemption to the pre-approval requirement—for supplements “intended to affect the structure or function” of the body *provided* that they carry prominent FDA-disclaimers. 21 U.S.C. § 343(r)(6)(A), (C); *see also* 21 U.S.C. § 321(g)(1) (“A food, dietary ingredient, or dietary supplement for which a truthful and not misleading statement is made in accordance with section 343(r)(6) of this title is not a drug under [21 U.S.C. § 321(g)(1)(C)] solely because the label or the labeling contains such a statement.”); 21 C.F.R. § 101.93(b)-(d).

55. Disclaimers must read, “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” 21 U.S.C. § 343(r)(6); *see also* 21 C.F.R. § 101.93(c).

56. The disclaimer requirement aligns with FDA’s statement that “few dietary supplements have been the subjects of adequately designed clinical trials.” *See* Regulations on

⁴ *See also* Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body, 65 Fed. Reg. 1000, 1001, 2000 WL 4559 (Jan. 6, 2000) (“Section 505 of the [FFDCA] (21 U.S.C. 355) requires that new drugs (see section 201(p) of the [FFDCA]) be shown to be safe and effective for their intended uses before marketing.”).

1 Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure
2 or Function of the Body, 65 Fed. Reg. 1000, 1003, 2000 WL 4559 (Jan. 6, 2000).⁵

3 57. Also, without the disclaimers, structure/function claims convey to consumers
4 therapeutic drug claims, because it is “possible to describe almost all products intended to treat or
5 prevent disease in terms of their effects on the structure or function of the body, without
6 mentioning the disease itself.” *See* 65 Fed. Reg. at 1005; *see also id.* at 1013 (“Most disease
7 treatment or prevention claims, including claims about serious and life-threatening diseases, can
8 be described in a manner that will be easily understood by consumers without express reference to
9 a specific disease. . . . The distinction between implied and express disease claims is thus, in many
10 cases, a semantic one that has little, if any, practical meaning to consumers.”).

11 58. Such marketing dangerously encourages consumers to self-treat for serious
12 conditions without the benefit of a medical diagnosis or treatment. *Id.* at 1001, 1044-45.

13 59. In short, the purpose of the disclaimer is to “make sure that consumers understand
14 that structure/function claims are not reviewed by FDA prior to marketing, and to caution
15 consumers that dietary supplements bearing such claims are not for therapeutic uses.” *Id.* at 1007
16 (emphasis added).

17 60. The disclaimer must appear “on each panel or page” of a supplement label or
18 package that bears a health-related claim, 21 C.F.R. § 101.93(d), and it must be prominent.
19 21 U.S.C. § 343(r)(6).

20 61. As the FDA stated in 1997:

21 The [FDA] rejects the comments that stated that repetition of the
22 disclaimer on every panel or page where a statement made in
23 accordance with section 403(r)(6) of the act appears is unnecessary.
24 The agency concludes that to meet the statutory requirement that
25 the disclaimer be “contained” within the statement, *the disclaimer*
26 *must be within the same field of vision as the statement itself*.
Because the agency concludes that the placement of the disclaimer
anywhere on the same page or panel of labeling is equivalent to
meeting the requirement of being “contained,” each of the
suggestions for the placement of a single disclaimer on a product

27 ⁵ *See also id.* at 1003 (“[M]any marketed supplements have not been the subjects of adequate
28 studies to establish whether or not they are safe or effective, or the nature of the benefits they may
provide.”).

1 label (e.g., under the nutrition label, adjacent to the most prominent
2 claim) would not provide an acceptable alternative.

3 Food Labeling; Requirements for Nutrient Content Claims, Health Claims, and Statements of
4 Nutritional Support for Dietary Supplements, 62 Fed. Reg. 49,859, 49,864-65 (Sept. 23, 1997)
5 (emphasis added); *see also id.* at 49,864 (“FDA has evaluated the comments and concludes that
6 the placement of the disclaimer on a panel other than where the statement is made would not meet
7 the statutory requirement for the placement of the disclaimer. . . . Based on its experience with
8 asterisks within the nutrition label, the agency concludes that consumers are accustomed to using
9 asterisks on labels to associate two discrete pieces of important information *when they are in the*
10 *same field of vision.*” (emphasis added) (citation omitted)).

11 62. In the same Final Rule, the FDA went on to state that:

12 Statements provided for in section 403(r)(6) of the act are entirely
13 voluntary. All required information must first be considered in
14 designing labels. Moreover, the firm must consider that the
15 disclaimer must be prominent as required by the statute. Therefore,
16 there will be instances in which statements under section 403(r)(6)
17 of the act should not be used on a label or in labeling because it is
18 *not feasible* to accommodate both the required information and the
19 statutory requirement for prominence for the disclaimer.

20 *Id.* at 49,865-66 (emphasis added).

21 63. To be prominent, the disclaimer may not be crowded with non-required, or
22 voluntary, information or imagery and additionally must use bolded font *at least* 1/16th of an inch
23 in size. *See id.*; 21 C.F.R. § 101.93(e).

24 64. Failure to abide by the disclaimer requirements renders non-compliant supplements
25 misbranded, unapproved, and unlawful drugs under federal law. 21 U.S.C. §§ 321(g)(1), 331(d),
26 343(r)(6), 355(a).

27 65. California has expressly adopted federal labeling requirements as its own pursuant
28 to the Sherman Law, which provides that “[a]ll food labeling regulations and any amendments to
those regulations adopted pursuant to the federal act, in effect on January 1, 1993, or adopted on or
after that date shall be the food regulations of this state.” CAL. HEALTH & SAFETY CODE § 110100.

66. GNC fails to abide by the disclaimer requirements in labeling and marketing its Supplements.

67. GNC's Diabetic Supplement, for example, lacks the required disclaimers.

68. GNC omits the disclaimer from the front panel of the packaging for GNC's Diabetic Supplement, or the side panel, despite the presence of structure/function claims on both panels. *See* Images 1-2 (with arrows pointing to front of package panels on one dimensional images of multi-panel labels).

Images 1-2



///

///

///


///

///

///

///

///



GNC

MEGA MEN

Diabetic Support

Dietary Supplement

MULTIVITAMIN & NUTRITION PLAN

- Multivitamin with premium ingredients to support glucose metabolism*

Time-Release
90 CAPLETS

 **CLINICALLY STUDIED**

70. GNC's violation of the disclaimer requirement renders the labeling, marketing, and sale of GNC Supplements misbranded and unlawful.

71. GNC's failure to include the mandatory disclaimer also renders its Supplements unlawful drugs. New "drugs" requires pre-approval by the FDA prior to marketing and sale, *see* 21 U.S.C. §§ 331(d), 355(a), which pre-approval GNC has not obtained prior to its sales and marketing of the Supplements.⁶

B. GNC's Labeling and Packaging Claims Are Deceptive and Misleading.

72. As described above, GNC markets and labels its Supplements as correctly branded, lawful, FDA-approved, and/or of therapeutic value (intended to prevent or treat disease or conditions associated with disease), and does so deceptively and misleadingly.

73. GNC compounds its deceptive marketing with authoritative sounding embellishments like "clinically studied," "scientifically formulated," and "physician endorsed," and by implying therapeutic properties by referencing diseases or conditions linked to disease.

74. GNC's website embraces the deception. For example, one verified purchaser of Diabetes Support posted, "[k]eeps [my] glucose and A1C in check." Another stated that "GNC Mega Men Diabetic Support . . . has help [sic] in keeping my sugars down." And another posted that it helps "stabilize" sugars.⁷

75. GNC's omission of the mandatory disclaimers from Supplement panels is systemic. *See, e.g.*, Images 4-9 (with arrows pointing to front panels lacking disclaimers).

///

///

///

///

///


///




///


⁶ *See also* 65 Fed. Reg. at 1001.

⁷ *GNC Mega Men® Diabetic Support*, www.GNC.COM (2019), <http://bit.ly/2XCiFUP>.

Images 4-9







76. By contrast, Target brand proprietary “Up & Up” dietary supplements prominently display the mandated disclaimer on the front panel of their labels and elsewhere where structure/function claims appear. Target’s disclaimers are also not so crowded by voluntary statements and imagery as to lose prominence. *See* Image 10 (arrow pointing to bolded, set off, disclaimer on front panel).

Image 10



ECONOMIC INJURY

77. When purchasing the GNC Supplements, Plaintiffs read and relied on GNC’s labeling and marketing claims.

78. Based on the Supplements’ labeling, Plaintiffs believed the GNC Supplements had the aforementioned characteristics and benefits, including that they were lawful.

79. As a result, Plaintiffs received GNC Supplements that lacked the characteristics and/or benefits that they reasonably believed the products had.

80. Plaintiffs would not have purchased the GNC Supplements, purchased as many of them, and/or paid as much for them absent these sales, misrepresentations, and labeling and marketing practices.

81. Plaintiffs lost money as a result of GNC’s unlawful and deceptive and misleading conduct because Plaintiffs did not receive the products for which they believed they paid.

82. Plaintiffs altered their position to their detriment and suffered damages in an amount equal to the amounts they paid for the GNC Supplements they purchased.

83. Plaintiffs would purchase the GNC Supplements again in the future should they have the characteristics and/or the benefits marketed and labeled.

84. By engaging in unlawful sales and/or deceptive and misleading marketing, GNC reaped, and continues to reap, increased sales and profits, including with respect to its competitors.

85. GNC knows that the qualities and characteristics it labels and markets, as well as its omissions, are material to a consumer's decision to purchase its Supplements.

86. GNC deliberately cultivates these misperceptions through its marketing and labeling of its Supplements. Indeed, GNC relies and capitalizes on consumer misconceptions about its Supplements.

CLASS ACTION ALLEGATIONS

87. Pursuant to Rules 23(a), (b)(2), and (b)(3) of the Federal Rules of Civil Procedure, Plaintiffs bring this action individually and on behalf of three proposed subclasses defined as follows:

The California Subclass. All persons residing in the State of California who purchased one or more GNC proprietary brand supplements within the applicable limitations period.

The New York Subclass. All persons who purchased one or more of GNC proprietary brand supplements in the State of New York within the applicable limitations period.

The Nationwide Subclass. All persons in the United States who purchased one or more GNC proprietary brand supplements within the applicable state limitations periods.

88. Collectively, the California, New York, and Nationwide Subclasses constitute the "Class."

89. Excluded from the Class are: (a) Defendant; (b) Defendant's board members, executive-level officers, and attorneys, and immediate family members of any of the foregoing persons; (c) governmental entities; (d) the Court, the Court's immediate family, and the Court staff; and (e) any person that timely and properly excludes himself or herself from the Class in accordance with Court-approved procedures.

1 90. Certification of Plaintiffs' claims for class-wide treatment is appropriate because
 2 Plaintiffs can prove the elements of the claims on a class-wide basis using the same evidence as
 3 individual Class members would use to prove the elements in individual actions alleging the same
 4 claims.

5 91. **Numerosity.** The Class consists of many thousands of persons throughout the
 6 states of California, New York, and nationwide. The Class is so numerous that joinder of all
 7 members is impracticable, and the disposition of each of the Class's claims in a class action will
 8 benefit the parties and the Court.

9 92. **Commonality and Predominance.** Common questions of law and fact
 10 predominate over any questions affecting only individual Class members. These common
 11 questions have the capacity to generate common answers that will drive resolution of this action.
 12 These common questions include whether:

- 13 a. GNC committed the conduct alleged herein;
- 14 b. GNC's conduct constitutes the violations of laws alleged herein;
- 15 c. GNC acted willfully, recklessly, negligently, or with gross negligence in
 16 committing the violations of law alleged herein;
- 17 d. Plaintiffs and the Class members are entitled to injunctive relief; and
- 18 e. Plaintiffs and the Class members are entitled to restitution and damages.

19 93. Because they were subject to the same unlawful and deceptive marketing practices
 20 of the Supplements, and because they purchased the GNC proprietary brand supplements, all Class
 21 members were subject to the same wrongful conduct.

22 94. Absent GNC's material deceptions, misstatements, and omissions, Plaintiffs and
 23 the other Class members would not have purchased the GNC proprietary brand supplements.

24 95. **Typicality.** Plaintiffs' claims are typical of the claims of the Class because
 25 Plaintiffs and the Class members all purchased the GNC proprietary brand supplements and were
 26 injured thereby. The claims of Plaintiffs and the Class members are based on the same legal
 27 theories and arise from the same deceptive, misleading, and unlawful conduct.
 28

101. Plaintiffs Arora and Clinton bring this claim on behalf of the California Subclass for violation of the “unlawful” prong of California’s Unfair Competition Law, CAL. BUS. & PROF. CODE § 17200 *et seq.* (the “UCL”).

102. The UCL prohibits any “unlawful, unfair or fraudulent business act or practice.” CAL. BUS. & PROF. CODE § 17200.

103. Defendant’s acts, omissions, misrepresentations, practices, and non-disclosures concerning its proprietary brand supplements, as alleged herein, constitute “unlawful” business acts and practices in that they violate the FFDCa, as amended by DSHEA, and implementing regulations, including, at least, the following sections:

a. The requirement under 21 C.F.R. § 101.93(b) that dietary supplements include a disclaimer on each package or label panel stating a structure/function claim notifying the consumer that the FDA has not reviewed or approved of such claims and that the supplement is not intended to treat, cure, or prevent any disease;

b. The requirement that each disclaimer be prominent and not obscured or by voluntary claims and information. *Id.*; 21 U.S.C. § 403(r)(6)(C);

c. The requirement that all drugs receive pre-approval prior to being marketed and sold, including drugs that would otherwise qualify as dietary supplements were they to include proper disclaimers. *See* 21 U.S.C. § 343(r)(6);

d. The prohibition on introduction of misbranded dietary supplements into interstate commerce. 21 U.S.C. §§ 331, 333; and

e. The requirement prohibiting marketing claims that are “false or misleading in any particular.” 21 U.S.C. § 343(a)(1); 21 C.F.R. § 101.93(a)(3).

104. Each of GNC’s violations of federal law and regulations violates California’s Sherman Food, Drug, and Cosmetic Law, CAL. HEALTH & SAFETY CODE § 109875 *et seq.* (the “Sherman Law”), including, but not limited to, the following sections:

a. Section 110100 (adopting all FDA regulations as state regulations);

b. Section 110290 (“In determining whether the labeling or advertisement of a food . . . is misleading, all representations made or suggested by statement, word, design, device, sound, or any combination of these, shall be taken into account.”);

c. Section 110390 (“It is unlawful for any person to disseminate any false advertisement of any food. . . . An advertisement is false if it is false or misleading in any particular.”);

d. Section 110395 (“It is unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any food . . . that is falsely advertised.”);

e. Section 110398 (“It is unlawful for any person to advertise any food, drug, device, or cosmetic that is adulterated or misbranded.”);

f. Section 110400 (“It is unlawful for any person to receive in commerce any food . . . that is falsely advertised or to deliver or proffer for delivery any such food”); and

g. Section 110660 (“Any food is misbranded if its labeling is false or misleading in any particular.”).

105. Each of the challenged omissions, statements, and actions by GNC violates the FFDCa, as amended by DSHEA, and the Sherman Law, and, consequently, violates the “unlawful” prong of the UCL.

106. GNC’s conduct is further “unlawful” because it violates California’s False Advertising Law, CAL. BUS. & PROF. CODE § 17500 *et seq.* (the “FAL”), and California’s Consumers Legal Remedies Act, CAL. CIV. CODE § 1750 *et seq.* (the “CLRA”), as discussed in the claims below.

107. GNC leveraged its omissions and deception to induce Plaintiffs Arora and Clinton, and the members of the California Subclass, to purchase Supplements that were of different characteristics, value, and/or quality than advertised.

108. GNC’s unlawful sales and deceptive marketing and labeling caused Plaintiffs Arora and Clinton and the members of the California Subclass to suffer injury in fact and to lose money or property, as it denied them the benefit of the bargain. Had Plaintiffs and the members of the California Subclass been aware of GNC’s unlawful marketing, labeling, and/or sales tactics, they

1 would not have purchased GNC Supplements, purchased as much of GNC Supplements, or paid
2 as much for GNC Supplements.

3 109. In accordance with California Business and Professions Code section 17203,
4 Plaintiffs Arora and Clinton seek an order enjoining GNC from continuing to conduct business
5 through unlawful, unfair, and/or fraudulent acts and practices and to commence a corrective
6 advertising campaign.

7 110. Plaintiffs Arora and Clinton also seek an order for the disgorgement and restitution
8 of all monies from the sale of the GNC proprietary brand supplements that GNC unjustly acquired
9 through acts of unlawful, unfair, and/or fraudulent competition.

10 111. Therefore, Plaintiffs Arora and Clinton pray for relief as set forth below.

11 **SECOND CLAIM FOR RELIEF**
12 **Violation of California's Unfair Competition Law**
13 **CAL. BUS. & PROF. CODE § 17200 *et seq.***
14 **Unfair and Fraudulent Conduct Prongs**
15 **(By Plaintiffs Arora and Clinton, on Behalf of the California Subclass)**

16 112. Plaintiffs Arora and Clinton repeat each and every allegation contained in the
17 paragraphs above and incorporate such allegations by reference herein.

18 113. Plaintiffs Arora and Clinton bring this claim on behalf of the California Subclass
19 for violation of the “unfair” and “fraudulent” prongs of the UCL.

20 114. The UCL prohibits any “unlawful, unfair or fraudulent business act or practice.”
21 CAL. BUS. & PROF. CODE § 17200.

22 115. Defendant's false and misleading labeling and marketing of the GNC Supplements
23 as alleged herein constitute “unfair” business acts and practices because such conduct is immoral,
24 unscrupulous, and offends public policy. Further, the gravity of GNC's conduct outweighs any
25 conceivable benefit of such conduct.

26 116. The acts, omissions, misrepresentations, practices, and non-disclosures of GNC, as
27 alleged herein, constitute “fraudulent” business acts and practices, because GNC's conduct is false
28 and misleading to reasonable consumers, including Plaintiffs Arora and Clinton and the members
of the California Subclass.

117. GNC's marketing and labeling of its Supplements is likely to deceive reasonable consumers about their characteristics and value.

118. GNC either knew or reasonably should have known that the claims in the marketing, advertising, and labeling of the dietary supplements were likely to deceive reasonable consumers.

119. In accordance with California Business & Professions Code section 17203, Plaintiffs Arora and Clinton seek an order enjoining GNC from continuing to conduct business through unlawful, unfair, and/or fraudulent acts and practices and to commence a corrective advertising campaign.

120. Plaintiffs Arora and Clinton also seek an order for the disgorgement and restitution of all monies from the sale of GNC Supplements that were unjustly acquired through acts of unlawful, unfair, and/or fraudulent competition.

121. Therefore, Plaintiffs Arora and Clinton pray for relief as set forth below.

THIRD CLAIM FOR RELIEF
Violation of California's False Advertising Law
CAL. BUS. & PROF. CODE § 17500 *et seq.*
(By Plaintiffs Arora and Clinton, on Behalf of the California Subclass)

122. Plaintiffs Arora and Clinton repeat each and every allegation contained in the paragraphs above and incorporate such allegations by reference herein.

123. Plaintiffs Arora and Clinton bring this claim on behalf of the California Subclass for violation of the FAL.

124. The FAL prohibits making any false or misleading advertising claim. CAL. BUS. & PROF. CODE § 17500.

125. As alleged herein, GNC, in its marketing and labeling of its Supplements makes "false [and] misleading advertising claim[s]" that deceive consumers about their characteristics and value.

126. In reliance on these false and misleading marketing claims, Plaintiffs Arora and Clinton and the members of the California Subclass purchased GNC Supplements believing that

1 they were: properly branded, lawful, FDA-approved, and/or intended to prevent, treat, or cure
2 disease.

3 127. GNC knew or should have known that the marketing and labeling of the
4 Supplements was likely to deceive consumers.

5 128. As a result, Plaintiffs Arora and Clinton and the California Subclass members seek
6 injunctive and equitable relief, restitution, and an order for the disgorgement of the funds by which
7 GNC was unjustly enriched.

8 129. Therefore, Plaintiffs Arora and Clinton pray for relief as set forth below.

9 **FOURTH CLAIM FOR RELIEF**
10 **Violation of California's Consumers Legal Remedies Act**
11 **CAL. CIV. CODE § 1750 *et seq.***
12 **(By Plaintiffs Arora and Clinton, on Behalf of the California Subclass)**
13 **(Injunctive Relief Only)**

14 130. Plaintiffs Arora and Clinton repeat each and every allegation contained in the
15 paragraphs above and incorporate such allegations by reference herein.

16 131. Plaintiffs Arora and Clinton bring this claim on behalf of the California Subclass
17 for violation of the CLRA, seeking injunctive relief only.

18 132. The CLRA adopts a statutory scheme prohibiting various deceptive practices in
19 connection with the conduct of a business providing goods, property, or services primarily for
20 personal, family, or household purposes.

21 133. GNC's policies, acts, and practices were designed to, and did, result in the purchase
22 and use of GNC's Supplements primarily for personal, family, or household purposes, and
23 violated and continue to violate the following sections of the CLRA:

24 a. Section 1770(a)(5), which prohibits representing that goods have a
25 particular composition or contents that they do not have;

26 b. Section 1770(a)(5), which also prohibits representing that goods have
27 characteristics, uses, or benefits that they do not have;

28 c. Section 1770(a)(7), which prohibits representing that goods are of a
particular standard, quality, or grade if they are of another;

d. Section 1770(a)(9), which prohibits advertising goods with intent not to sell them as advertised; and

e. Section 1770(a)(16), which prohibits representing that the subject of a transaction has been supplied in accordance with a previous representation when it has not.

134. As a result, in accordance with California Civil Code section 1780(a)(2), Plaintiffs Arora and Clinton and the members of the California Subclass have suffered irreparable harm and seek injunctive relief in the form of an order:

a. Enjoining GNC from continuing to engage in the deceptive practices described above;

b. Requiring GNC to provide public notice of the true nature of its Supplements; and

c. Enjoining GNC from such deceptive business practices in the future.

135. Pursuant to section 1782 of the CLRA, Plaintiffs Arora and Clinton hereby notify GNC in writing of its particular violations of section 1770 of the CLRA and are demanding, among other actions, that GNC cease marketing its Supplements as set forth in detail above and correct, repair, replace, or otherwise rectify GNC Supplements that are in violation of section 1770. If GNC fails to respond to Plaintiffs Arora and Clinton's demand within 30 days of this notice, pursuant to section 1782 of the CLRA, Plaintiffs will amend this Class Action Complaint to request, in addition to the above relief, statutory damages, actual damages, punitive damages, interest, and attorneys' fees.

136. Therefore, Plaintiffs Arora and Clinton pray for relief as set forth below.

FIFTH CLAIM FOR RELIEF
Violation of New York's Consumer Protection from Deceptive Acts and Practices Law
N.Y. GEN. BUS. LAW § 349 *et seq.*
(By Plaintiff Johnston, on Behalf of the New York Subclass)

137. Plaintiff Johnston repeats each and every allegation contained in the paragraphs above and incorporates such allegations by reference herein.

138. Plaintiff Johnston brings this claim on behalf of the New York Subclass for violation of section 349 of New York’s Consumer Protection from Deceptive Acts and Practices Law, N.Y. GEN. BUS. LAW § 349 *et seq.*

139. Section 349 prohibits “[d]eceptive acts or practices in the conduct of any business, trade or commerce or in the furnishing of any service in [the State of New York].” N.Y. GEN. BUS. LAW § 349(a).

140. GNC’s labeling and marketing of the GNC brand proprietary supplements, as alleged herein, constitute “deceptive” acts and practices, as such conduct misled Plaintiff Johnston and the New York Subclass as to the characteristics and value of the GNC brand proprietary supplements.

141. Subsection (h) of section 349 grants private plaintiffs a right of action for violation of New York’s Consumer Protection from Deceptive Acts and Practices Law, as follows:

In addition to the right of action granted to the attorney general pursuant to this section, any person who has been injured by reason of any violation of this section may bring an action in his own name to enjoin such unlawful act or practice, an action to recover his actual damages or fifty dollars, whichever is greater, or both such actions. The court may, in its discretion, increase the award of damages to an amount not to exceed three times the actual damages up to one thousand dollars, if the court finds the defendant willfully or knowingly violated this section. The court may award reasonable attorney’s fees to a prevailing plaintiff.

N.Y. GEN. BUS. LAW § 349(h).

142. In accordance with subsection (h) of section 349, Plaintiff Johnston seeks an order enjoining GNC from continuing the unlawful deceptive acts and practices set out above. Absent a Court order enjoining the unlawful deceptive acts and practices, GNC will continue its deceptive and misleading marketing campaign and, in doing so, irreparably harm each of the New York Subclass members.

143. As a consequence of GNC’s deceptive acts and practices, Plaintiff Johnston and other members of the New York Subclass suffered an ascertainable loss of monies. By reason of the foregoing, Plaintiff Johnston and other members of the New York Subclass also seek actual

1 damages or statutory damages of \$50 per violation, whichever is greater, as well as punitive
2 damages. N.Y. GEN. BUS. LAW § 349(h).

3 144. Therefore, Plaintiff Johnston prays for relief as set forth below.

4 **SIXTH CLAIM FOR RELIEF**
5 **Violation of New York’s Consumer Protection from Deceptive Acts and Practices Law**
6 **N.Y. GEN. BUS. LAW § 350 *et seq.***
7 **(By Plaintiff Johnston, on Behalf of the New York Subclass)**

8 145. Plaintiff Johnston repeats each and every allegation contained in the paragraphs
9 above and incorporates such allegations by reference herein.

10 146. Plaintiff Johnston brings this claim on behalf of the New York Subclass for
11 violation of section 350 of New York’s Consumer Protection from Deceptive Acts and Practices
12 Law, N.Y. GEN. BUS. LAW § 350.

13 147. Section 350 prohibits “[f]alse advertising in the conduct of any business, trade or
14 commerce or in the furnishing of any service in [the State of New York].” N.Y. GEN. BUS. LAW §
15 350.

16 148. New York General Business Law section 350-a defines “false advertising” as
17 “advertising, including labeling, of a commodity, or of the kind, character, terms or conditions of
18 any employment opportunity if such advertising is misleading in a material respect.” N.Y. GEN.
19 BUS. LAW § 350-a.1. The section also provides that advertising can be false by omission, as it
20 further defines “false advertising” to include “advertising [that] fails to reveal facts material in the
21 light of such representations with respect to the commodity . . . to which the advertising relates.”
22 *Id.*

23 149. GNC’s labeling, marketing, and advertising of GNC brand proprietary
24 supplements, as alleged herein, are “misleading in a material respect” and, thus, constitute “false
25 advertising,” as they falsely represent the GNC brand proprietary supplements as consisting of
26 characteristics and lawfulness that they do not possess.

27 150. Plaintiff Johnston seeks an order enjoining GNC from continuing this false
28 advertising. Absent enjoining this false advertising, GNC will continue to mislead Plaintiff
Johnston and the other members of the New York Subclass as to the characteristics of the GNC

1 brand proprietary supplements and, in doing so, irreparably harm each of the New York Subclass
2 members.

3 151. As a direct and proximate result of GNC's violation of New York General Business
4 Law section 350, Plaintiff Johnston and the other members of the New York Subclass have also
5 suffered an ascertainable loss of monies. By reason of the foregoing, Plaintiff Johnston and other
6 members of the New York Subclass also seek actual damages or statutory damages of \$500 per
7 violation, whichever is greater, as well as punitive damages. N.Y. GEN. BUS. LAW § 350-e.

8 152. Therefore, Plaintiff Johnston prays for relief as set forth below.

9 **SEVENTH CLAIM FOR RELIEF**
10 **Unjust Enrichment / Quasi-Contract**
11 **(By Plaintiffs Arora, Clinton, and Johnston, on Behalf of the Nationwide Subclass)**

12 153. Plaintiffs incorporate by reference each allegation set forth above.

13 154. As a result of GNC's unlawful and misleading labeling, marketing, and sale of the
14 Supplements, GNC was enriched at the expense of Plaintiffs.

15 155. GNC sold Supplements to Plaintiffs that were not capable of being sold legally and
16 that were worthless.

17 156. Plaintiffs paid a premium price for the Supplements.

18 157. It is against equity and good conscience to permit GNC to retain the ill-gotten
19 benefits received from Plaintiffs and the Nationwide Subclass members given that the
20 Supplements were not what GNC purported them to be.

21 158. It would be unjust and inequitable for GNC to retain the benefit, warranting
22 restitutionary disgorgement to Plaintiffs and the Nationwide Subclass members of all monies paid
23 for the Supplements, and/or all monies paid for which Plaintiffs and the Nationwide Subclass
24 members did not receive benefit.

25 159. As a direct and proximate result of GNC's actions, Plaintiffs and the Nationwide
26 Subclass members have suffered damages in an amount to be proven at trial.

27 160. Therefore, Plaintiffs pray for relief as set forth below.
28

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs, individually and on behalf of all members of the Class, pray for judgment as follows:

A. certifying the proposed Class under Federal Rule of Civil Procedure 23(a), (b)(2), and (b)(3), as set forth above;

B. declaring that Defendant is financially responsible for notifying the Class members of the pendency of this suit;

C. declaring that Defendant has committed the violations of law alleged herein;

D. providing for any and all injunctive relief the Court deems appropriate;

E. awarding statutory damages in the maximum amount for which the law provides;

F. awarding monetary damages, including but not limited to any compensatory, incidental, or consequential damages in an amount that the Court or jury will determine, in accordance with applicable law;

G. providing for any and all equitable monetary relief the Court deems appropriate;

H. awarding punitive or exemplary damages in accordance with proof and in an amount consistent with applicable precedent;

I. awarding Plaintiffs their reasonable costs and expenses of suit, including attorneys' fees;

J. awarding pre- and post-judgment interest to the extent the law allows; and

K. for such further relief as this Court may deem just and proper.

///

///

///

///

///

///

///

///

JURY DEMAND

Pursuant to Rule 38 of the Federal Rules of Civil Procedure, Plaintiffs hereby demand a trial by jury on all claims so triable.

Dated: May 3, 2019

KAPLAN FOX & KILSHEIMER LLP

By: /s/ Laurence D. King
Laurence D. King

Laurence D. King (SBN 206423)
lking@kaplanfox.com
Mario M. Choi (SBN 243409)
mchoi@kaplanfox.com
350 Sansome Street, Suite 400
San Francisco, CA 94104
Telephone: (415) 772-4700
Facsimile: (415) 772-4709

KAPLAN FOX & KILSHEIMER LLP
Maia C. Kats (to be admitted *pro hac vice*)
mkats@kaplanfox.com
6109 32nd Place, NW
Washington, DC 20015
Telephone: (202) 669-0658

REESE LLP
Michael R. Reese (SBN 206773)
mreese@reesellp.com
George V. Granade (SBN 316050)
ggranade@reesellp.com
100 West 93rd Street, 16th Floor
New York, New York 10025
Telephone: (212) 643-0500
Facsimile: (212) 253-4272

*Counsel for Plaintiffs Richa Arora, Randy Clinton,
and Walter Johnston and the Proposed Class*